Johnson & Johnson (NYSE:JNJ) Shares Down 2.3% – What’s Next?

Johnson & Johnson (NYSE:JNJ)’s stock price fell 2.3% during mid-day trading on Tuesday . The company traded as low as $266.88 and last traded at $269.0370. Approximately 7,767,583 shares changed hands during mid-day trading, a decline of 4% from the average session volume of 8,120,712 shares. The stock had previously closed at $275.23.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Jim Cramer described the recent pullback in Johnson & Johnson as a buying opportunity, arguing that investors should “buy the dip.” His comments may provide short-term sentiment support, although they represent an opinion rather than a new company catalyst. Cramer Says It’s Time to Buy the Dip on JNJ
• Positive Sentiment: JNJ announced that 24 abstracts covering bipolar mania, depression and schizophrenia will be presented at Psych Congress 2026. The first presentation of pivotal Phase 3 CAPLYTA data in bipolar mania, along with new SPRAVATO analyses, highlights potential pipeline expansion in neuropsychiatry. The commercial impact remains dependent on the detailed data and subsequent regulatory or sales progress. Johnson & Johnson Neuropsychiatry Data
• Neutral Sentiment: Market commentary continues to group JNJ with defensive stocks that may offer stability and dividends as investors await CPI data and the Federal Reserve’s rate decision. This could support demand for the shares, but higher interest rates can also limit the appeal of mature dividend stocks. Five Defensive Stocks to Watch
• Negative Sentiment: An executive sale valued at approximately $9.23 million adds a modest insider-selling signal. One transaction does not establish a broader trend, but it may weigh on sentiment. Johnson & Johnson Insider Selling

Analysts Set New Price Targets

Several equities analysts recently issued reports on JNJ shares. HSBC set a $290.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Monday, July 6th. TD Cowen raised their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Argus set a $300.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 29th. Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 3rd. Finally, Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $272.83.

Johnson & Johnson Stock Down 2.3%

The firm has a market capitalization of $648.35 billion, a P/E ratio of 31.17, a PEG ratio of 2.63 and a beta of 0.24. The firm’s 50 day moving average is $262.32 and its two-hundred day moving average is $245.30. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same period last year, the business posted $2.77 EPS. Johnson & Johnson’s revenue was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Research analysts predict that Johnson & Johnson will post 11.61 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be issued a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Insiders Place Their Bets

In related news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,779,963.81. This trade represents a 50.06% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 97,569 shares of company stock worth $25,476,044. 0.16% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Johnson & Johnson

A number of institutional investors have recently added to or reduced their stakes in JNJ. Blueline Advisors LLC bought a new position in shares of Johnson & Johnson in the 4th quarter valued at $25,000. Outlook Capital Management LLC bought a new position in Johnson & Johnson in the second quarter valued at about $28,000. Semmax Financial Advisors Inc. boosted its stake in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of Johnson & Johnson by 946.7% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company’s stock valued at $32,000 after purchasing an additional 142 shares in the last quarter. Finally, MidAtlantic Capital Management Inc. bought a new stake in shares of Johnson & Johnson during the fourth quarter worth about $37,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.